Much of the attention on AstraZeneca PLC in the past couple of years has focused on its blooming oncology franchise but its top earner is the pipeline-in-a-product Farxiga and sales of the SGLT2 inhibitor, which is approved type 2 diabetes, heart failure and chronic kidney disease, have soared again in the second quarter.
Speaking to Scrip as the UK-headquartered giant unveiled its latest set of financials, CEO Pascal Soriot said that Farxiga/Forxiga (dapagliflozin) was "the poster child of where the industry can deliver. It is a medicine that is accessible to almost everybody around the world [and] billions of people can benefit from it
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?